Agent for preventing and/or treating cachexia

Details Agent for preventing and/or treating cachexia Agent for preventing and/or treating cachexia

2006-11-21

2006-11-21

Borin, Michael (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07138372

ABSTRACT:
The present invention provides an agent for preventing and/or treating cachexia comprising TCF-II as an effective ingredient. An agent for preventing and treating cachexia caused by cancer, acquired immunodeficient syndrome (AIDS), cardiac diseases, infectious disease, shock, burn, endotoxinemia, organ inflammation, surgery, diabetes, collagen diseases, radiotherapy, chemotherapy is provided by the present invention.

REFERENCES:
patent: 3904753 (1975-09-01), Sonenberg et al.
patent: 4076701 (1978-02-01), Burton et al.
patent: 4481137 (1984-11-01), Ohnishi et al.
patent: 4490549 (1984-12-01), Johnson
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4777241 (1988-10-01), Irikura et al.
patent: 4822605 (1989-04-01), Powell
patent: 4870163 (1989-09-01), Rubin et al.
patent: 5091511 (1992-02-01), Sone et al.
patent: 5328836 (1994-07-01), Shima et al.
patent: 5362716 (1994-11-01), Kmiecik et al.
patent: 5432267 (1995-07-01), Kusama et al.
patent: 5510327 (1996-04-01), Hayasaka et al.
patent: 5547856 (1996-08-01), Godowski et al.
patent: 5587359 (1996-12-01), Higashio et al.
patent: 5589451 (1996-12-01), Wilson
patent: 5606029 (1997-02-01), Degen
patent: 5648233 (1997-07-01), Yamaguchi et al.
patent: 5648273 (1997-07-01), Bottaro et al.
patent: 5658742 (1997-08-01), Higashio et al.
patent: 5703047 (1997-12-01), Wilson
patent: 5703048 (1997-12-01), Roos et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5714461 (1998-02-01), Masunaga et al.
patent: 5760177 (1998-06-01), Iwanaga et al.
patent: 5776464 (1998-07-01), Nakamura
patent: 5821223 (1998-10-01), Rubin et al.
patent: 5998370 (1999-12-01), Arai
patent: 6306827 (2001-10-01), Kinosaki et al.
patent: 6333309 (2001-12-01), Higashio
patent: 2218864 (1997-10-01), None
patent: 2100720 (2003-03-01), None
patent: 2116192 (2005-05-01), None
patent: 0 322 084 (1989-06-01), None
patent: 0 456 188 (1991-11-01), None
patent: 0 498 680 (1992-08-01), None
patent: 0 519 728 (1992-12-01), None
patent: 0 588 477 (1994-03-01), None
patent: 0 604 184 (1994-06-01), None
patent: 0 604 185 (1994-06-01), None
patent: 0 462 277 (1995-06-01), None
patent: 0 672 685 (1995-09-01), None
patent: 0 724 884 (1996-07-01), None
patent: 0 462 549 (1996-08-01), None
patent: 0 757 994 (1997-02-01), None
patent: 0 821 969 (1998-02-01), None
patent: 0 461 560 (1998-11-01), None
patent: 0 891 778 (1999-01-01), None
patent: 0 539 590 (1999-03-01), None
patent: 0 914 829 (1999-05-01), None
patent: 0 925 791 (1999-06-01), None
patent: 0 950 416 (1999-10-01), None
patent: 0 982 037 (2000-01-01), None
patent: 0 612 530 (2000-08-01), None
patent: 0 653 211 (2001-10-01), None
patent: 10-68400 (1989-03-01), None
patent: 5-244976 (1993-09-01), None
patent: 6-40935 (1994-02-01), None
patent: 6-40938 (1994-02-01), None
patent: 06040934 (1994-02-01), None
patent: 6-56692 (1994-03-01), None
patent: 6-116299 (1994-04-01), None
patent: 06340546 (1994-12-01), None
patent: 081176007 (1996-07-01), None
patent: 08231418 (1996-09-01), None
patent: 10-29951 (1998-02-01), None
patent: 10-194986 (1998-07-01), None
patent: 10-273446 (1998-10-01), None
patent: WO90/10651 (1990-09-01), None
patent: WO91/03254 (1991-03-01), None
patent: WO93/08821 (1993-05-01), None
patent: WO93/13066 (1993-07-01), None
patent: WO94/14845 (1994-07-01), None
patent: WO96/20004 (1996-07-01), None
patent: WO96/20214 (1996-07-01), None
patent: WO96/28423 (1996-09-01), None
patent: WO96/32960 (1996-10-01), None
patent: WO98/40096 (1998-09-01), None
patent: WO98/41230 (1998-09-01), None
patent: WO98/43665 (1998-10-01), None
patent: WO99/47155 (1999-09-01), None
Ashorn, et al., (1990), “An Inhibitor of the Protease Blocks Maturation of Human and Simian Immunodeficiency Viruses and Spread of Infection,”Proc. Natl. Acad. Sci.,87:7472-7476.
Baldwin, et al., (1995), “Structure of HIV-1 Protease with KNI-272, A Tight-Binding Transition-State Analog Containing Allophenylnorstatine,”Structure,3(6):81-588.
Bone, (1991), “The Pathogenesis of Sepsis,”Annals of Internal Medicine,115(6):457-469.
Cerra et al., (1987), “Hypermetabolism, organ failure, and metabolic support,”Surgery,vol. 101, 1-14.
Cross et al., (1993), “Choice of Bacteria in Animal Models of Sepsis,”Infection and Immunity,61:2741-2747.
Debouck, et al., (1990), “Human Immunodeficiency Virus Protease: A Target for AIDS Therapy,” Drug Development Research, 21:1-17.
Deitch, (1992), “Multiple Organ Failure,”Annals of Surgery,216(2):117-134.
Deitch et al., (1999), “Prevention of Multiple Organ Failure,”Surgical Clinics of North America,79(6):1471-1488.
Dube et al., (1988), “Glycosylation at Specific Sites of Erythropoietin Is Essential for Biosynthesis, Secretion, and Biological Function,”Journal of Biological Chemistry,263(33):17516-17521.
Fehey et al., (1992), “Status of Immune-Based Therapies In HIV Infection and AIDS”Clin., Exp. Immunol.,88:1-5.
Fink et al., (1990), “Laboratory Models of Sepsis and Shock,”Journal of Surgical Research,49:186-196.
Glauser et al., (1991), “Septic Shock: Pathogenesis,”The Lancet,338:732-736.
Goodman & Gilman,The Pharmacological Basis of Therapeutics,9thEdition, pp. 1654-1659.
Goto, M. et al., “Production of Recombinant Human Erythropoietin in mammalian Cells: Host-Cell Dependency of the Biological Activity of the Cloned Glycoprotein.”Bio/Technology,vol. 6, pp. 67-71 (Jan. 1988).
Gross et al., (1993), “Inflammatory Mediators and Cytokines—New Aspects of the Pathophysiology and Assessment of Severity of Acute Pancreatitis?,”Hepato-Gastroenterol.,40:522-530.
Gulnik, et al., (1995), “Kinetic Characterization and Cross-Resistance Patterns of HIV-I Protease Mutants A Selected under Drug Pressure,”Biochemistry,34:9282-9287.
Haynes et al., (1996), “Update on the Issues of HIV Vaccine Development,”Annals of Medicine,28:39-41.
Hernandez, et al., (1992), “Characterization of the Effects of Human Placental HGF on Rat Hepatocytes,”Journal of Cellular Physiology,150:116-121.
Hoffman et al., (1992), “Scatter Factor is a Glycoprotein but Glycosylation is not Required for its Activity”,Biochimica et Biophysica Acta,1120:343-350.
Holzheimer et al., (1997), “The Challenge of Postoperative Infections: Does the Surgeon Make a Difference,”Infection Control and Hospital Epideomiology,18(6):449-456.
Holzheimer, (2001), “Antibiotic Induced Endotoxin Release and Clinical Sepsis: a Review,”Journal of Chemotherapy,13 (1):159-172.
Horton et al., (1987), “Hemodynamic Function in Acute Pancreatitis,”Surgery,103:538-546.
Hughes et al., (1996), “Inhibition of TNFa Improves Survival in an Experimental Model of Acute Pancreatitis,”American Surgeon,62:8-13.
Humphrey et al., (1997), “Removal of Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitors from Preparations of Immature HIV-1 Virions Does Not Result in an Increase in Infectivity or the Appearance of Mature Morphology,”Antimicrobial Agents and Chemotherapy,:1017-1023.
Humphrey et al., (1996), “A Phase 1 Trial of HIV Protease Inhibitor KNI-272 in Patients with AIDS of Symptomatic HIV Infections,”Int. Conf. AIDSJu. 7-12, 1996, 11:77 (abstract No. Mo.B.1132).
Jiji Press, “Anti-AIDS Drug Tests Go to Britain,”Japan Times,(1995).
Kageyama et al., (1993), “In Vitro Anti-Human Immunodeficiency Virus (HIV) Activities of Transition State Mimetic HIV Protease Inhibitors Containing Allophenylnorstatine,”Antimicrobial Agents and Chemotherapy,: 810-817.
Kageyama et al., (1992), “In Vitro Inhibition of Human Immunodeficiency Virus (HIV) Type 1 Replication by C2 Symmetry-Based HIV Protease Inhibitors as Single Agents or in Combinations,”ANtimicrobial Agents and Chemotherap,:926-933.
Kaneshima et al., (1991), “Human Immunodeficiency Virus Infection of Human Lymph Nodes in the SCID-hu Mouse,”Proc. Natl. Acad. Sci.,

Affiliated with

Also associated with

Rating

Agent for preventing and/or treating cachexia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for preventing and/or treating cachexia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for preventing and/or treating cachexia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3688300